PGR decision: May 05, 2020
|
AIA Review #
|
Filing Date
|
Institution Date
|
Petitioner
|
Patent
|
Respondent
|
Status
|
|
PGR2019-00003
|
10/16/2018
|
05/07/2019
|
Grunenthal GmbH
|
9,867,839
|
Antecip Bioventures II LLC
|
Some Challenged Claims Unpatentable
|
US 9,867,839 (ANTECIP BIOVENTURES II LLC; Exp: Mar. 27, 2035)
1. A method of treating pain associated with a joint comprising: administering neridronic acid in an acid form or a salt form to a patient who has suffered for at least 3 months with 1) pain associated with a joint and 2) a pain intensity of 5 or greater measured using the 0-10 numerical rating scale (NRS) or 5 cm or greater using the 10 cm visual analog scale (VAS).
15. A method of treating pain associated with a joint comprising: orally administering zoledronic acid in an acid form or a salt form to a patient having 1) pain associated with a joint and 2) a pain intensity of 5 or greater measured using the 0-10 NRS or 5 cm or greater using the 10 cm VAS, wherein a total of about 400 mg to about 600 mg of zoledronic acid is administered in 2 or 3 individual doses within a period of about a month.
ORDER:
Claims 1–14 of the ’839 patent are unpatentable; and
Claims 15–30 of the ’839 patent are not shown to be unpatentable.
Leave a Reply